Deverra Therapeutics, with a valuation of $59.84 million, is raising funds on StartEngine. It is a clinical-stage biotech company that provides universal donor treatments for accessible immune cell therapies. Deverra Therapeutics’ immune cell therapies are affordable, safe, and readily available to reinvent the way therapies are delivered for cancer and other life-threatening illnesses. The company’s lead clinical asset, Dilanubicel, has shown significant remission rates in a phase 2 leukemia clinical trial with 184 patient infusions. Michael Yurkowsky and Colleen Delaney founded Deverra Therapeutics in September 2020. The current crowdfunding campaign has a minimum target of $14,999.93 and a maximum target of $1.23 million. The campaign proceeds will be used for research and clinical development.